Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches

Beth Snyder Bulik

Senior Editor

Gilead Sciences is now halfway through its 10-year pledge in the US southern states to tackle HIV through community grants, and looking back while also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

At Jefferies, all that manufacturers want to talk about is GLP-1s

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Are programs with compounded GLP-1s safe for your population?

Gilead tracks five years of HIV grant giv­ing in hard-hit US South, and dou­bles down on new ap­proach­es

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

At Jefferies, all that manufacturers want to talk about is GLP-1s

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Are programs with compounded GLP-1s safe for your population?